Benzinga | Nov 5, 2020 09:09AM EST

Catalyst Biosciences Announces Poster Presentation At 62nd Annual American Society Of Hematology Conference Dec. 6



SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) -- or MarzAA, the Company's subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 62nd Annual American Society of Hematology (ASH) meeting being held virtually December 5-8, 2020.

Poster presentation details: The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy andPoster Safety of Subcutaneous Marzeptacog Alfa (activated) for on-DemandTitle: Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with InhibitorsPresenting Linda Neuman, M.D., M.B.A., vice president, clinical development,Author: Catalyst BiosciencesDate/Time: Sunday, December 6, 2020 / 7 am PT